Farletuzumab, a monoclonal antibody targeting FOLR1, induces the death of cancer cells expressing FOLR1 by antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and inhibition of Lyn kinase substrate phosphorylation [26–28]. The gene discussed is FOLR1; the disease is cancer.